BACKGROUND: Review of the historical growth in annual vaccination coverage across countries and regions can better inform decision makers' development of future goals and strategies to improve routine vaccination services. METHODS: Using the World Health Organization (WHO) and the United Nations Children's Fund estimates of annual national third dose of diphtheria-tetanus-pertussis-containing vaccine (DTP3) and third dose of polio vaccine (POL3) coverage for 1980-2009, we calculated the mean absolute annual rate of change in national DTP3 coverage among all countries (globally) and among countries within each WHO region, as well as the number of years taken by each region to reach specific regional coverage levels. Last, we assessed differences in mean absolute annual rate of change in DTP3 coverage, stratified by baseline level of DTP3 coverage. RESULTS: During the 1980s, global DTP3 coverage increased a mean of 5.3 percentage points/year. Annual rate of change decreased to 0.5 percentage points/year in the 1990s and then increased to 0.9 percentage points/year during the 2000s. Mean annual rate of change in coverage across all countries was highest (9.2 percentage points) when national coverage levels were 26%-30% and lowest (-0.9 percentage points) when national coverage levels were 96%-100%. Regional differences existed as both WHO South-East Asia Region and WHO African Region countries experienced mean negative DTP3 coverage growth at lower coverage levels (81%-85%) than other regions. The regions that have achieved 95% DTP3 coverage (Americas, Western Pacific, and European) took 25-29 years to reach that level from a level of 50% DTP3 coverage. POL3 coverage change trends were similar to described DTP3 coverage change trends. CONCLUSIONS: Mean national coverage growth patterns across all regions are nonlinear as coverage levels increase. Saturation points of mean 0 percentage-point growth in annual coverage varies by region and require further investigation. The achievement of >90% routine coverage is observed to take decades, which has implications for disease eradication and elimination initiatives. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Review of the historical growth in annual vaccination coverage across countries and regions can better inform decision makers' development of future goals and strategies to improve routine vaccination services. METHODS: Using the World Health Organization (WHO) and the United Nations Children's Fund estimates of annual national third dose of diphtheria-tetanus-pertussis-containing vaccine (DTP3) and third dose of polio vaccine (POL3) coverage for 1980-2009, we calculated the mean absolute annual rate of change in national DTP3 coverage among all countries (globally) and among countries within each WHO region, as well as the number of years taken by each region to reach specific regional coverage levels. Last, we assessed differences in mean absolute annual rate of change in DTP3 coverage, stratified by baseline level of DTP3 coverage. RESULTS: During the 1980s, global DTP3 coverage increased a mean of 5.3 percentage points/year. Annual rate of change decreased to 0.5 percentage points/year in the 1990s and then increased to 0.9 percentage points/year during the 2000s. Mean annual rate of change in coverage across all countries was highest (9.2 percentage points) when national coverage levels were 26%-30% and lowest (-0.9 percentage points) when national coverage levels were 96%-100%. Regional differences existed as both WHO South-East Asia Region and WHO African Region countries experienced mean negative DTP3 coverage growth at lower coverage levels (81%-85%) than other regions. The regions that have achieved 95% DTP3 coverage (Americas, Western Pacific, and European) took 25-29 years to reach that level from a level of 50% DTP3 coverage. POL3 coverage change trends were similar to described DTP3 coverage change trends. CONCLUSIONS: Mean national coverage growth patterns across all regions are nonlinear as coverage levels increase. Saturation points of mean 0 percentage-point growth in annual coverage varies by region and require further investigation. The achievement of >90% routine coverage is observed to take decades, which has implications for disease eradication and elimination initiatives. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Michael McQuestion; Devendra Gnawali; Clifford Kamara; Diana Kizza; Helene Mambu-Ma-Disu; Jonas Mbwangue; Ciro de Quadros Journal: Health Aff (Millwood) Date: 2011-06 Impact factor: 6.301
Authors: Anthony Burton; Roeland Monasch; Barbara Lautenbach; Marta Gacic-Dobo; Maryanne Neill; Rouslan Karimov; Lara Wolfson; Gareth Jones; Maureen Birmingham Journal: Bull World Health Organ Date: 2009-07 Impact factor: 9.408
Authors: Rajesh Sharma; Mehak Nanda; Claudio Fronterre; Paul Sewagudde; Anna E Ssentongo; Kelsey Yenney; Nina D Arhin; John Oh; Forster Amponsah-Manu; Paddy Ssentongo Journal: Front Public Health Date: 2022-04-25
Authors: Rebecca Mary Casey; Lee McCalla Hampton; Blanche-Philomene Melanga Anya; Marta Gacic-Dobo; Mamadou Saliou Diallo; Aaron Stuart Wallace Journal: Pan Afr Med J Date: 2017-06-21
Authors: Alain Poy; Maya M V X van den Ent; Stephen Sosler; Alan R Hinman; Sidney Brown; Samir Sodha; Daniel C Ehlman; Aaron S Wallace; Richard Mihigo Journal: J Infect Dis Date: 2017-07-01 Impact factor: 5.226
Authors: Kristin VanderEnde; Marta Gacic-Dobo; Mamadou S Diallo; Laura M Conklin; Aaron S Wallace Journal: MMWR Morb Mortal Wkly Rep Date: 2018-11-16 Impact factor: 17.586
Authors: Xiang Li; Christinah Mukandavire; Zulma M Cucunubá; Susy Echeverria Londono; Kaja Abbas; Hannah E Clapham; Mark Jit; Hope L Johnson; Timos Papadopoulos; Emilia Vynnycky; Marc Brisson; Emily D Carter; Andrew Clark; Margaret J de Villiers; Kirsten Eilertson; Matthew J Ferrari; Ivane Gamkrelidze; Katy A M Gaythorpe; Nicholas C Grassly; Timothy B Hallett; Wes Hinsley; Michael L Jackson; Kévin Jean; Andromachi Karachaliou; Petra Klepac; Justin Lessler; Xi Li; Sean M Moore; Shevanthi Nayagam; Duy Manh Nguyen; Homie Razavi; Devin Razavi-Shearer; Stephen Resch; Colin Sanderson; Steven Sweet; Stephen Sy; Yvonne Tam; Hira Tanvir; Quan Minh Tran; Caroline L Trotter; Shaun Truelove; Kevin van Zandvoort; Stéphane Verguet; Neff Walker; Amy Winter; Kim Woodruff; Neil M Ferguson; Tini Garske Journal: Lancet Date: 2021-01-30 Impact factor: 79.321
Authors: M Carolina Danovaro-Holliday; Emily Dansereau; Dale A Rhoda; David W Brown; Felicity T Cutts; Marta Gacic-Dobo Journal: Vaccine Date: 2018-07-21 Impact factor: 3.641